Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ITRM Stock Forecast 2025-2026
$0.99
Current Price
$39.88M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ITRM Price Targets
+809.1%
To High Target of $9.00
+607.1%
To Median Target of $7.00
+405.1%
To Low Target of $5.00
ITRM Price Momentum
0.0%
1 Week Change
+7.6%
1 Month Change
-20.2%
1 Year Change
-44.1%
Year-to-Date Change
-67.2%
From 52W High of $3.02
+22.5%
From 52W Low of $0.81
📊 TOP ANALYST CALLS
Did ITRM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Iterum is one of their latest high-conviction picks.
Latest ITRM Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, ITRM has a bullish consensus with a median price target of $7.00 (ranging from $5.00 to $9.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $0.99, the median forecast implies a 607.1% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 809.1% upside. Conversely, the most conservative target is provided by Ed Arce at HC Wainwright & Co., suggesting a 405.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ITRM Analyst Ratings
2
Buy
0
Hold
0
Sell
ITRM Price Target Range
Low
$5.00
Average
$7.00
High
$9.00
Current: $0.99
Latest ITRM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ITRM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Assumes | $9.00 |
| Sep 10, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $5.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $5.00 |
| Jun 21, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| May 31, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| May 14, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Apr 30, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Apr 1, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Mar 6, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Feb 7, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Upgrade | $6.00 |
| Jul 27, 2021 | Gabelli & Co. | Kevin Kedra | Hold | Upgrade | $0.00 |
| Jul 26, 2021 | HC Wainwright & Co. | Ed Arce | Neutral | Downgrade | $0.00 |
| May 28, 2021 | Gabelli & Co. | Hold | Upgrade | $0.00 | |
| Mar 15, 2021 | HC Wainwright & Co. | Buy | Upgrade | $0.00 | |
| Oct 1, 2020 | SVB Leerink | Ami Fadia | Market Perform | Maintains | $1.50 |
| Jun 16, 2020 | HC Wainwright & Co. | Neutral | Downgrade | $0.00 | |
| Jun 2, 2020 | SVB Leerink | Market Perform | Maintains | $1.00 | |
| Jun 2, 2020 | RBC Capital | Sector Perform | Downgrade | $2.00 | |
| Dec 11, 2019 | RBC Capital | Gregory Renza | Outperform | Maintains | $10.00 |
| Dec 11, 2019 | SVB Leerink | Ami Fadia | Market Perform | Downgrade | $4.00 |
Iterum Therapeutics plc (ITRM) Competitors
The following stocks are similar to Iterum based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ITRM
Iterum Therapeutics
mkt cap
39.64M
Iterum Therapeutics plc (ITRM) Financial Data
Iterum Therapeutics plc has a market capitalization of $39.88M with a P/E ratio of -0.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +607.1%.
Valuation Metrics
Market Cap
$39.88M
Enterprise Value
$59.27M
P/E Ratio
-0.8x
PEG Ratio
-1.5x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+31.9%
Current Ratio
3.7x
Debt/Equity
-12.5x
ROE
+607.1%
ROA
-38.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Iterum Therapeutics plc (ITRM) Business Model
About Iterum Therapeutics plc
What They Do
Develops antibiotics for bacterial infections.
Business Model
Iterum Therapeutics plc operates as a clinical-stage pharmaceutical company focused on developing innovative antibiotics to treat drug-resistant bacterial infections. It primarily generates revenue through the development and commercialization of its lead product, sulopenem, which targets multi-drug resistant Gram-negative infections, particularly in urinary tract and intra-abdominal infections.
Additional Information
Headquartered in Dublin, Ireland, the company is positioned in a market that is increasingly seeking new treatment options due to the rise in antibiotic resistance. Iterum Therapeutics not only aims to improve patient care but also to influence healthcare policies and practices on a global scale.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
9
CEO
Mr. Corey N. Fishman
Country
Ireland
IPO Year
2018
Website
www.iterumtx.comIterum Therapeutics plc (ITRM) Latest News & Analysis
Latest News
Quick Summary
Iterum Therapeutics announced the U.S. commercial launch of ORLYNVAH TM by Q4 2025, marking the first oral penem available in the U.S. A conference call is scheduled for today at 4:30 p.m. ET.
Why It Matters
The launch of ORLYNVAH TM, the first oral penem in the U.S., signals new revenue potential for Iterum Therapeutics, enhancing investor interest in its growth prospects and market impact.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Iterum Therapeutics announced that Pfizer has extended the payment term for a $20 million regulatory milestone to October 25, 2029.
Why It Matters
The extension of Pfizer's $20 million milestone payment to Iterum Therapeutics until 2029 indicates financial stability for Iterum, potentially affecting its stock value and investment attractiveness.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Iterum Therapeutics plc will host its Q1 2025 Earnings Conference Call on May 13, 2025, at 8:30 AM ET, featuring key executives including CEO Corey Fishman.
Why It Matters
The earnings call indicates potential financial performance insights and strategic updates for Iterum Therapeutics, impacting stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Iterum Therapeutics plans to launch ORLYNVAH TM for uncomplicated urinary tract infections by Q4 2025 and has extended its cash runway into 2026. A conference call is scheduled for today at 8:30 am ET.
Why It Matters
The potential launch of ORLYNVAH could drive revenue growth, while an extended cash runway suggests financial stability, both key factors for stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Iterum Therapeutics will release Q1 2025 financial results on May 13, 2025, before U.S. markets open, followed by a conference call at 8:30 a.m. ET.
Why It Matters
The upcoming financial results from Iterum Therapeutics could indicate the company's performance and growth potential, impacting stock prices and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares
1 month ago
Quick Summary
Iterum Therapeutics closed a registered direct offering, selling 5,555,556 shares at $0.90 each to a single institutional investor, aimed at funding its antibiotic development efforts.
Why It Matters
Iterum Therapeutics raised $5 million through a direct offering, which may enhance its capital for development. This could impact stock valuation and future growth potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ITRM Stock
What is Iterum Therapeutics plc's (ITRM) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Iterum Therapeutics plc (ITRM) has a median price target of $7.00. The highest price target is $9.00 and the lowest is $5.00.
Is ITRM stock a good investment in 2025?
According to current analyst ratings, ITRM has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.99. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ITRM stock?
Wall Street analysts predict ITRM stock could reach $7.00 in the next 12 months. This represents a 607.1% increase from the current price of $0.99. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Iterum Therapeutics plc's business model?
Iterum Therapeutics plc operates as a clinical-stage pharmaceutical company focused on developing innovative antibiotics to treat drug-resistant bacterial infections. It primarily generates revenue through the development and commercialization of its lead product, sulopenem, which targets multi-drug resistant Gram-negative infections, particularly in urinary tract and intra-abdominal infections.
What is the highest forecasted price for ITRM Iterum Therapeutics plc?
The highest price target for ITRM is $9.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 809.1% increase from the current price of $0.99.
What is the lowest forecasted price for ITRM Iterum Therapeutics plc?
The lowest price target for ITRM is $5.00 from Ed Arce at HC Wainwright & Co., which represents a 405.1% increase from the current price of $0.99.
What is the overall ITRM consensus from analysts for Iterum Therapeutics plc?
The overall analyst consensus for ITRM is bullish. Out of 6 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are ITRM stock price projections?
Stock price projections, including those for Iterum Therapeutics plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 21, 2025 3:26 AM UTC